Share-based Payment Arrangement, Expense in USD of Relay Therapeutics, Inc. from Q2 2019 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Relay Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense history and change rate from Q2 2019 to Q4 2024.
  • Relay Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2024 was $17,635,000, a 8.47% decline year-over-year.
  • Relay Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2024 was $94,139,000, a 9.43% increase year-over-year.
  • Relay Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $94,139,000, a 9.43% increase from 2023.
  • Relay Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $86,031,000, a 53.2% increase from 2022.
  • Relay Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $56,138,000, a 15.9% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Relay Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $94,139,000 $17,635,000 -$1,632,000 -8.5% 01 Oct 2024 31 Dec 2024 10-K 26 Feb 2025 2024 FY
Q3 2024 $95,771,000 $22,484,000 +$649,000 +3% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2024 2024 Q3
Q2 2024 $95,122,000 $26,832,000 +$3,421,000 +15% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2024 2024 Q2
Q1 2024 $91,701,000 $27,188,000 +$5,670,000 +26% 01 Jan 2024 31 Mar 2024 10-Q 02 May 2024 2024 Q1
Q4 2023 $86,031,000 $19,267,000 +$5,450,000 +39% 01 Oct 2023 31 Dec 2023 10-K 26 Feb 2025 2024 FY
Q3 2023 $80,581,000 $21,835,000 +$8,116,000 +59% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $72,465,000 $23,411,000 +$8,264,000 +55% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $64,201,000 $21,518,000 +$8,063,000 +60% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q1
Q4 2022 $56,138,000 $13,817,000 +$3,599,000 +35% 01 Oct 2022 31 Dec 2022 10-K 26 Feb 2025 2024 FY
Q3 2022 $52,539,000 $13,719,000 +$1,301,000 +10% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $51,238,000 $15,147,000 -$1,000,000 -6.2% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $52,238,000 $13,455,000 +$3,784,000 +39% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $48,454,000 $10,218,000 -$4,326,000 -30% 01 Oct 2021 31 Dec 2021 10-K 22 Feb 2024 2023 FY
Q3 2021 $52,780,000 $12,418,000 +$489,000 +4.1% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $52,291,000 $16,147,000 +$12,115,000 +300% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $40,176,000 $9,671,000 +$8,216,000 +565% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $31,960,000 $14,544,000 01 Oct 2020 31 Dec 2020 10-K 23 Feb 2023 2022 FY
Q3 2020 $11,929,000 +$10,681,000 +856% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $4,032,000 +$2,946,000 +271% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $1,455,000 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1
Q3 2019 $1,248,000 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2020 Q3
Q2 2019 $1,086,000 01 Apr 2019 30 Jun 2019 10-Q 27 Aug 2020 2020 Q2

Relay Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $94,139,000 +$8,108,000 +9.4% 01 Jan 2024 31 Dec 2024 10-K 26 Feb 2025 2024 FY
2023 $86,031,000 +$29,893,000 +53% 01 Jan 2023 31 Dec 2023 10-K 26 Feb 2025 2024 FY
2022 $56,138,000 +$7,684,000 +16% 01 Jan 2022 31 Dec 2022 10-K 26 Feb 2025 2024 FY
2021 $48,454,000 +$16,494,000 +52% 01 Jan 2021 31 Dec 2021 10-K 22 Feb 2024 2023 FY
2020 $31,960,000 +$27,504,000 +617% 01 Jan 2020 31 Dec 2020 10-K 23 Feb 2023 2022 FY
2019 $4,456,000 01 Jan 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.